Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
This study has been completed.
Study NCT00431015 Information provided by Infinity Pharmaceuticals, Inc.
First Received on January 31, 2007. Last Updated on December 6, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
More general conditions related to this trial
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Interventions listed in this trial
Sponsors listed in this trial
Infinity Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers